Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a severe form of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). MASH is a growing public health concern due to its increasing prevalence, driven by factors like obesity, type 2 diabetes, and metabolic syndrome. MASH can progress to advanced liver scarring (fibrosis) and cirrhosis, increasing the risk of liver cancer and …Read More >

Abstract: Emerging as a major global health concern, metabolic dysfunction-associated steatohepatitis (MASH) is closely linked to obesity, type 2 diabetes, and other metabolic disorders. Advances in metabolic research have positioned glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a promising therapeutic option for MASH, extending their use beyond diabetes and obesity management. This article examines the …Read More >

The hepatobiliary system (comprised of the liver, gallbladder, and bile ducts) plays an important role in digestion and in the biotransformation and disposition of endogenous molecules and drugs. Hepatobiliary diseases range from minor infection or scarring to serious conditions such as cancer. At this year’s EASL conference, WuXi AppTec showcased our comprehensive platform of hepatobiliary-related …Read More >

Selecting preclinical in vivo models that are reflective of clinical outcome is a key challenge in the development of new therapies to treat fibrotic diseases.  To accelerate research focused on pulmonary, renal, and liver fibrosis, WuXi AppTec has established a series of in vivo models supported with anti-fibrotic efficacy data.  Our platform also includes a …Read More >

In this case study, we demonstrate clinical relevance of the HFD+CCL4 (high-fat diet and carbon tetrachloride) NASH animal model. Improvement of hepatic fibrosis has been a challenging endpoint in NASH clinical trials and selecting animal models that show anti-fibrotic efficacy has been equally challenging for the preclinical development of new NASH drugs.  Our findings indicate …Read More >

Chronic HBV infection (CHB) is a major contributor to liver-related deaths worldwide. The ultimate endpoint of CHB treatment is sustained HBV surface antigen (HBsAg) loss. Here, we report the design of a series of HBV surface antigen inhibitors which promotes reduction of HBV antigens in vitro and in vivo. https://pubmed.ncbi.nlm.nih.gov/36089112/

WuXi AppTec scientists recently contributed to a research study published in the journal Hepatology, characterizing the efficacy of prodrug DF-006 for treating chronic hepatitis B infection. DF-006 is an orally active agonist of alpha‐kinase 1, a pattern recognition receptor involved in the stimulation of innate immunity.  The authors show that DF‐006 is efficacious in hepatitis …Read More >

WuXi AppTec scientists recently contributed to a research article in the Royal Society of Chemistry describing the large-scale synthesis of a potent and selective inhibitor of Notum carboxylesterase (an enzyme that suppresses Wnt signaling pathways).  By employing a modified Sakai reaction as the key step, a one-pot synthesis of this Notum inhibitor was developed, enabling …Read More >

We offer a wide range of oligonucleotide services, including: Sequence design Knockdown effect in cell lines and primary cells Splicing analysis Functional assays and assessment of off-target effects Transgenic, HDI and AAV mouse models GalNAc-ASGPR delivery system and customized assays for other delivery systems Stability and protein-protein binding assays Delivery/RISC PK in mouse, rat, and …Read More >